CDC Advisers Begin Two-Day Review of Vaccine Guidelines, Propose Risk-Based COVID-19 Shot Recommendations for Older Adults

19 posts • GPT (4.1 mini)

Updated Apr 16, 2025, 06:19 PM

The U.S. Centers for Disease Control and Prevention (CDC) advisory panel, the Advisory Committee on Immunization Practices (ACIP), has commenced a two-day meeting after a nearly two-month delay to review vaccine guidelines, including those for COVID-19, HPV, flu, RSV, and chikungunya vaccines. A majority of the CDC's COVID-19 vaccine work group now supports ending the agency's pandemic-era recommendation for universal annual COVID-19 vaccination. Instead, they favor a narrower, risk-based approach focusing on older adults and individuals with underlying conditions that increase the risk of severe disease. This shift marks a potential change in immunization policy, as previous recommendations for COVID-19 vaccines were more broadly applied. The panel is also considering lowering the age recommendation for RSV vaccines and voting on recommendations for other vaccines such as RSV and chikungunya. Discussions include data on mRNA vaccine safety, with some advisors raising concerns about injury reports. The meeting occurs amid scrutiny from health officials and public debate on vaccine policies.

More breaking stories on DeepNewz — updated live.

#CDC

Related Prediction Markets

Which vaccines will RFK end recommendations for?

Vaccine for new COVID disease in 2025?

•

View market suggestions→

Sources

reuters.com(4)cbsnews.com(4)jp.reuters.com(2)theepochtimes.com(2)

BioPharma Dive

@BioPharmaDive

CDC panel mulls changes to COVID shot recommendations https://t.co/iLr3yxEzgd $PFE $MRNA $NVAX by @Lilah_Alvarado

FiercePharma

@FiercePharma

CDC vaccine panel review indicates potential changes to COVID, HPV immunization policies https://t.co/3FTsmliutI

Independent Medical Alliance

@Honest_Medicine

As the Advisory Committee on Immunization Practices meets, they need to prioritize the mRNA study showing historic levels of injury. https://t.co/ElOjmRZdlQ